IBDEI063 ; ; 01-MAY-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 01, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,14793,1,4,0)
 ;;=4^C94.41
 ;;^UTILITY(U,$J,358.3,14793,2)
 ;;=^5001844
 ;;^UTILITY(U,$J,358.3,14794,0)
 ;;=D62.^^62^698^18
 ;;^UTILITY(U,$J,358.3,14794,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14794,1,3,0)
 ;;=3^Acute Posthemorrhagic Anemia
 ;;^UTILITY(U,$J,358.3,14794,1,4,0)
 ;;=4^D62.
 ;;^UTILITY(U,$J,358.3,14794,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,14795,0)
 ;;=C92.41^^62^698^19
 ;;^UTILITY(U,$J,358.3,14795,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14795,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,14795,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,14795,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,14796,0)
 ;;=C92.40^^62^698^20
 ;;^UTILITY(U,$J,358.3,14796,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14796,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,14796,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,14796,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,14797,0)
 ;;=D56.0^^62^698^21
 ;;^UTILITY(U,$J,358.3,14797,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14797,1,3,0)
 ;;=3^Alpha Thalassemia
 ;;^UTILITY(U,$J,358.3,14797,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,14797,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,14798,0)
 ;;=D63.1^^62^698^23
 ;;^UTILITY(U,$J,358.3,14798,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14798,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,14798,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,14798,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,14799,0)
 ;;=D63.0^^62^698^24
 ;;^UTILITY(U,$J,358.3,14799,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14799,1,3,0)
 ;;=3^Anemia in Neoplastic Disease
 ;;^UTILITY(U,$J,358.3,14799,1,4,0)
 ;;=4^D63.0
 ;;^UTILITY(U,$J,358.3,14799,2)
 ;;=^321978
 ;;^UTILITY(U,$J,358.3,14800,0)
 ;;=D63.8^^62^698^22
 ;;^UTILITY(U,$J,358.3,14800,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14800,1,3,0)
 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,14800,1,4,0)
 ;;=4^D63.8
 ;;^UTILITY(U,$J,358.3,14800,2)
 ;;=^5002343
 ;;^UTILITY(U,$J,358.3,14801,0)
 ;;=C22.3^^62^698^27
 ;;^UTILITY(U,$J,358.3,14801,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14801,1,3,0)
 ;;=3^Angiosarcoma of Liver
 ;;^UTILITY(U,$J,358.3,14801,1,4,0)
 ;;=4^C22.3
 ;;^UTILITY(U,$J,358.3,14801,2)
 ;;=^5000936
 ;;^UTILITY(U,$J,358.3,14802,0)
 ;;=D61.9^^62^698^28
 ;;^UTILITY(U,$J,358.3,14802,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14802,1,3,0)
 ;;=3^Aplastic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,14802,1,4,0)
 ;;=4^D61.9
 ;;^UTILITY(U,$J,358.3,14802,2)
 ;;=^5002342
 ;;^UTILITY(U,$J,358.3,14803,0)
 ;;=D56.1^^62^698^30
 ;;^UTILITY(U,$J,358.3,14803,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14803,1,3,0)
 ;;=3^Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,14803,1,4,0)
 ;;=4^D56.1
 ;;^UTILITY(U,$J,358.3,14803,2)
 ;;=^340495
 ;;^UTILITY(U,$J,358.3,14804,0)
 ;;=C83.79^^62^698^32
 ;;^UTILITY(U,$J,358.3,14804,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14804,1,3,0)
 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,14804,1,4,0)
 ;;=4^C83.79
 ;;^UTILITY(U,$J,358.3,14804,2)
 ;;=^5001600
 ;;^UTILITY(U,$J,358.3,14805,0)
 ;;=C83.70^^62^698^33
 ;;^UTILITY(U,$J,358.3,14805,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14805,1,3,0)
 ;;=3^Burkitt Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,14805,1,4,0)
 ;;=4^C83.70
 ;;^UTILITY(U,$J,358.3,14805,2)
 ;;=^5001591
 ;;^UTILITY(U,$J,358.3,14806,0)
 ;;=D09.0^^62^698^40
 ;;^UTILITY(U,$J,358.3,14806,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14806,1,3,0)
 ;;=3^Carcinoma in Situ of Bladder
 ;;^UTILITY(U,$J,358.3,14806,1,4,0)
 ;;=4^D09.0
 ;;^UTILITY(U,$J,358.3,14806,2)
 ;;=^267742
 ;;^UTILITY(U,$J,358.3,14807,0)
 ;;=D06.9^^62^698^41
 ;;^UTILITY(U,$J,358.3,14807,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14807,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix
 ;;^UTILITY(U,$J,358.3,14807,1,4,0)
 ;;=4^D06.9
 ;;^UTILITY(U,$J,358.3,14807,2)
 ;;=^5001941
 ;;^UTILITY(U,$J,358.3,14808,0)
 ;;=D06.0^^62^698^43
 ;;^UTILITY(U,$J,358.3,14808,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14808,1,3,0)
 ;;=3^Carcinoma in Situ of Endocervix
 ;;^UTILITY(U,$J,358.3,14808,1,4,0)
 ;;=4^D06.0
 ;;^UTILITY(U,$J,358.3,14808,2)
 ;;=^5001938
 ;;^UTILITY(U,$J,358.3,14809,0)
 ;;=D06.1^^62^698^44
 ;;^UTILITY(U,$J,358.3,14809,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14809,1,3,0)
 ;;=3^Carcinoma in Situ of Exocervix
 ;;^UTILITY(U,$J,358.3,14809,1,4,0)
 ;;=4^D06.1
 ;;^UTILITY(U,$J,358.3,14809,2)
 ;;=^5001939
 ;;^UTILITY(U,$J,358.3,14810,0)
 ;;=D06.7^^62^698^42
 ;;^UTILITY(U,$J,358.3,14810,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14810,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix,Other Parts
 ;;^UTILITY(U,$J,358.3,14810,1,4,0)
 ;;=4^D06.7
 ;;^UTILITY(U,$J,358.3,14810,2)
 ;;=^5001940
 ;;^UTILITY(U,$J,358.3,14811,0)
 ;;=D04.9^^62^698^45
 ;;^UTILITY(U,$J,358.3,14811,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14811,1,3,0)
 ;;=3^Carcinoma in Situ of Skin
 ;;^UTILITY(U,$J,358.3,14811,1,4,0)
 ;;=4^D04.9
 ;;^UTILITY(U,$J,358.3,14811,2)
 ;;=^5001925
 ;;^UTILITY(U,$J,358.3,14812,0)
 ;;=C91.11^^62^698^48
 ;;^UTILITY(U,$J,358.3,14812,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14812,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
 ;;^UTILITY(U,$J,358.3,14812,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,14812,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,14813,0)
 ;;=C91.10^^62^698^49
 ;;^UTILITY(U,$J,358.3,14813,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14813,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
 ;;^UTILITY(U,$J,358.3,14813,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,14813,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,14814,0)
 ;;=C92.11^^62^698^50
 ;;^UTILITY(U,$J,358.3,14814,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14814,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
 ;;^UTILITY(U,$J,358.3,14814,1,4,0)
 ;;=4^C92.11
 ;;^UTILITY(U,$J,358.3,14814,2)
 ;;=^5001793
 ;;^UTILITY(U,$J,358.3,14815,0)
 ;;=C92.10^^62^698^51
 ;;^UTILITY(U,$J,358.3,14815,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14815,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
 ;;^UTILITY(U,$J,358.3,14815,1,4,0)
 ;;=4^C92.10
 ;;^UTILITY(U,$J,358.3,14815,2)
 ;;=^5001792
 ;;^UTILITY(U,$J,358.3,14816,0)
 ;;=D47.1^^62^698^52
 ;;^UTILITY(U,$J,358.3,14816,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14816,1,3,0)
 ;;=3^Chronic Myeloproliferative Disease
 ;;^UTILITY(U,$J,358.3,14816,1,4,0)
 ;;=4^D47.1
 ;;^UTILITY(U,$J,358.3,14816,2)
 ;;=^5002256
 ;;^UTILITY(U,$J,358.3,14817,0)
 ;;=C82.69^^62^698^53
 ;;^UTILITY(U,$J,358.3,14817,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14817,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,14817,1,4,0)
 ;;=4^C82.69
 ;;^UTILITY(U,$J,358.3,14817,2)
 ;;=^5001530
 ;;^UTILITY(U,$J,358.3,14818,0)
 ;;=C82.60^^62^698^54
 ;;^UTILITY(U,$J,358.3,14818,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14818,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,14818,1,4,0)
 ;;=4^C82.60
 ;;^UTILITY(U,$J,358.3,14818,2)
 ;;=^5001521
 ;;^UTILITY(U,$J,358.3,14819,0)
 ;;=D56.2^^62^698^55
 ;;^UTILITY(U,$J,358.3,14819,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14819,1,3,0)
 ;;=3^Delta-Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,14819,1,4,0)
 ;;=4^D56.2
 ;;^UTILITY(U,$J,358.3,14819,2)
 ;;=^340496
 ;;^UTILITY(U,$J,358.3,14820,0)
 ;;=D75.9^^62^698^56
 ;;^UTILITY(U,$J,358.3,14820,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14820,1,3,0)
 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
 ;;^UTILITY(U,$J,358.3,14820,1,4,0)
 ;;=4^D75.9
 ;;^UTILITY(U,$J,358.3,14820,2)
 ;;=^5002393
 ;;^UTILITY(U,$J,358.3,14821,0)
 ;;=D59.0^^62^698^59
 ;;^UTILITY(U,$J,358.3,14821,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14821,1,3,0)
 ;;=3^Drug-Induced Autoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,14821,1,4,0)
 ;;=4^D59.0
 ;;^UTILITY(U,$J,358.3,14821,2)
 ;;=^5002323
 ;;^UTILITY(U,$J,358.3,14822,0)
 ;;=D59.2^^62^698^60
 ;;^UTILITY(U,$J,358.3,14822,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14822,1,3,0)
 ;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,14822,1,4,0)
 ;;=4^D59.2
 ;;^UTILITY(U,$J,358.3,14822,2)
 ;;=^5002325
 ;;^UTILITY(U,$J,358.3,14823,0)
 ;;=R59.9^^62^698^63
 ;;^UTILITY(U,$J,358.3,14823,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14823,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Unspec
 ;;^UTILITY(U,$J,358.3,14823,1,4,0)
 ;;=4^R59.9
 ;;^UTILITY(U,$J,358.3,14823,2)
 ;;=^5019531
 ;;^UTILITY(U,$J,358.3,14824,0)
 ;;=D47.3^^62^698^64
 ;;^UTILITY(U,$J,358.3,14824,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14824,1,3,0)
 ;;=3^Essential Thrombocythemia
 ;;^UTILITY(U,$J,358.3,14824,1,4,0)
 ;;=4^D47.3
 ;;^UTILITY(U,$J,358.3,14824,2)
 ;;=^5002258
 ;;^UTILITY(U,$J,358.3,14825,0)
 ;;=C82.09^^62^698^65
 ;;^UTILITY(U,$J,358.3,14825,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14825,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,14825,1,4,0)
 ;;=4^C82.09
 ;;^UTILITY(U,$J,358.3,14825,2)
 ;;=^5001470
 ;;^UTILITY(U,$J,358.3,14826,0)
 ;;=C82.00^^62^698^66
 ;;^UTILITY(U,$J,358.3,14826,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14826,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Unspec Site
 ;;^UTILITY(U,$J,358.3,14826,1,4,0)
 ;;=4^C82.00
 ;;^UTILITY(U,$J,358.3,14826,2)
 ;;=^5001461
 ;;^UTILITY(U,$J,358.3,14827,0)
 ;;=C82.19^^62^698^67
 ;;^UTILITY(U,$J,358.3,14827,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14827,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,14827,1,4,0)
 ;;=4^C82.19
 ;;^UTILITY(U,$J,358.3,14827,2)
 ;;=^5001480
 ;;^UTILITY(U,$J,358.3,14828,0)
 ;;=C82.10^^62^698^68
 ;;^UTILITY(U,$J,358.3,14828,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14828,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Unspec Site
 ;;^UTILITY(U,$J,358.3,14828,1,4,0)
 ;;=4^C82.10
 ;;^UTILITY(U,$J,358.3,14828,2)
 ;;=^5001471
 ;;^UTILITY(U,$J,358.3,14829,0)
 ;;=C82.29^^62^698^69
 ;;^UTILITY(U,$J,358.3,14829,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14829,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,14829,1,4,0)
 ;;=4^C82.29
 ;;^UTILITY(U,$J,358.3,14829,2)
 ;;=^5001490
 ;;^UTILITY(U,$J,358.3,14830,0)
 ;;=C82.20^^62^698^70
 ;;^UTILITY(U,$J,358.3,14830,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14830,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Unspec Site
 ;;^UTILITY(U,$J,358.3,14830,1,4,0)
 ;;=4^C82.20
 ;;^UTILITY(U,$J,358.3,14830,2)
 ;;=^5001481
 ;;^UTILITY(U,$J,358.3,14831,0)
 ;;=C82.39^^62^698^71
 ;;^UTILITY(U,$J,358.3,14831,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14831,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,14831,1,4,0)
 ;;=4^C82.39
 ;;^UTILITY(U,$J,358.3,14831,2)
 ;;=^5001500
 ;;^UTILITY(U,$J,358.3,14832,0)
 ;;=C82.30^^62^698^72
 ;;^UTILITY(U,$J,358.3,14832,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14832,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Unspec Site
 ;;^UTILITY(U,$J,358.3,14832,1,4,0)
 ;;=4^C82.30
 ;;^UTILITY(U,$J,358.3,14832,2)
 ;;=^5001491
 ;;^UTILITY(U,$J,358.3,14833,0)
 ;;=C82.49^^62^698^73
 ;;^UTILITY(U,$J,358.3,14833,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14833,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,14833,1,4,0)
 ;;=4^C82.49
 ;;^UTILITY(U,$J,358.3,14833,2)
 ;;=^5001510
 ;;^UTILITY(U,$J,358.3,14834,0)
 ;;=C82.40^^62^698^74
 ;;^UTILITY(U,$J,358.3,14834,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14834,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
 ;;^UTILITY(U,$J,358.3,14834,1,4,0)
 ;;=4^C82.40
 ;;^UTILITY(U,$J,358.3,14834,2)
 ;;=^5001501
 ;;^UTILITY(U,$J,358.3,14835,0)
 ;;=C82.99^^62^698^75
 ;;^UTILITY(U,$J,358.3,14835,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14835,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,14835,1,4,0)
 ;;=4^C82.99
 ;;^UTILITY(U,$J,358.3,14835,2)
 ;;=^5001550
 ;;^UTILITY(U,$J,358.3,14836,0)
 ;;=C82.90^^62^698^76
 ;;^UTILITY(U,$J,358.3,14836,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14836,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Unspec Site
 ;;^UTILITY(U,$J,358.3,14836,1,4,0)
 ;;=4^C82.90
 ;;^UTILITY(U,$J,358.3,14836,2)
 ;;=^5001541
 ;;^UTILITY(U,$J,358.3,14837,0)
 ;;=R59.1^^62^698^61
 ;;^UTILITY(U,$J,358.3,14837,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14837,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Generalized
 ;;^UTILITY(U,$J,358.3,14837,1,4,0)
 ;;=4^R59.1
 ;;^UTILITY(U,$J,358.3,14837,2)
 ;;=^5019530
 ;;^UTILITY(U,$J,358.3,14838,0)
 ;;=C91.40^^62^698^80
 ;;^UTILITY(U,$J,358.3,14838,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14838,1,3,0)
 ;;=3^Hairy Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,14838,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,14838,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,14839,0)
 ;;=C91.42^^62^698^78
 ;;^UTILITY(U,$J,358.3,14839,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14839,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,14839,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,14839,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,14840,0)
 ;;=C91.41^^62^698^79
 ;;^UTILITY(U,$J,358.3,14840,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14840,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,14840,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,14840,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,14841,0)
 ;;=D57.01^^62^698^81
 ;;^UTILITY(U,$J,358.3,14841,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14841,1,3,0)
 ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
 ;;^UTILITY(U,$J,358.3,14841,1,4,0)
 ;;=4^D57.01
 ;;^UTILITY(U,$J,358.3,14841,2)
 ;;=^5002307
 ;;^UTILITY(U,$J,358.3,14842,0)
 ;;=D57.00^^62^698^82
 ;;^UTILITY(U,$J,358.3,14842,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14842,1,3,0)
 ;;=3^Hb-SS Disease w/ Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,14842,1,4,0)
 ;;=4^D57.00
 ;;^UTILITY(U,$J,358.3,14842,2)
 ;;=^5002306
 ;;^UTILITY(U,$J,358.3,14843,0)
 ;;=D57.02^^62^698^83
 ;;^UTILITY(U,$J,358.3,14843,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14843,1,3,0)
 ;;=3^Hb-SS Disease w/ Splenic Sequestration
 ;;^UTILITY(U,$J,358.3,14843,1,4,0)
 ;;=4^D57.02
 ;;^UTILITY(U,$J,358.3,14843,2)
 ;;=^5002308
 ;;^UTILITY(U,$J,358.3,14844,0)
 ;;=D68.32^^62^698^85
 ;;^UTILITY(U,$J,358.3,14844,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14844,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
 ;;^UTILITY(U,$J,358.3,14844,1,4,0)
 ;;=4^D68.32
 ;;^UTILITY(U,$J,358.3,14844,2)
 ;;=^5002357
 ;;^UTILITY(U,$J,358.3,14845,0)
 ;;=C22.2^^62^698^86
 ;;^UTILITY(U,$J,358.3,14845,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14845,1,3,0)
 ;;=3^Hepatoblastoma
 ;;^UTILITY(U,$J,358.3,14845,1,4,0)
 ;;=4^C22.2
 ;;^UTILITY(U,$J,358.3,14845,2)
 ;;=^5000935
 ;;^UTILITY(U,$J,358.3,14846,0)
 ;;=D58.9^^62^698^88
 ;;^UTILITY(U,$J,358.3,14846,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14846,1,3,0)
 ;;=3^Hereditary Hemolytic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,14846,1,4,0)
 ;;=4^D58.9
 ;;^UTILITY(U,$J,358.3,14846,2)
 ;;=^5002322
 ;;^UTILITY(U,$J,358.3,14847,0)
 ;;=C81.99^^62^698^89
 ;;^UTILITY(U,$J,358.3,14847,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14847,1,3,0)
 ;;=3^Hodgkin Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,14847,1,4,0)
 ;;=4^C81.99
 ;;^UTILITY(U,$J,358.3,14847,2)
 ;;=^5001460
 ;;^UTILITY(U,$J,358.3,14848,0)
 ;;=C81.90^^62^698^90
 ;;^UTILITY(U,$J,358.3,14848,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14848,1,3,0)
 ;;=3^Hodgkin Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,14848,1,4,0)
 ;;=4^C81.90
 ;;^UTILITY(U,$J,358.3,14848,2)
 ;;=^5001451
 ;;^UTILITY(U,$J,358.3,14849,0)
 ;;=D89.2^^62^698^91
 ;;^UTILITY(U,$J,358.3,14849,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14849,1,3,0)
 ;;=3^Hypergammaglobulenemia,Unspec
 ;;^UTILITY(U,$J,358.3,14849,1,4,0)
 ;;=4^D89.2
 ;;^UTILITY(U,$J,358.3,14849,2)
 ;;=^5002455
 ;;^UTILITY(U,$J,358.3,14850,0)
 ;;=D05.12^^62^698^94
 ;;^UTILITY(U,$J,358.3,14850,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14850,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Left Breast
 ;;^UTILITY(U,$J,358.3,14850,1,4,0)
 ;;=4^D05.12
 ;;^UTILITY(U,$J,358.3,14850,2)
 ;;=^5001931
 ;;^UTILITY(U,$J,358.3,14851,0)
 ;;=D05.11^^62^698^95
 ;;^UTILITY(U,$J,358.3,14851,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14851,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Right Breast
 ;;^UTILITY(U,$J,358.3,14851,1,4,0)
 ;;=4^D05.11
 ;;^UTILITY(U,$J,358.3,14851,2)
 ;;=^5001930
 ;;^UTILITY(U,$J,358.3,14852,0)
 ;;=D05.10^^62^698^96
 ;;^UTILITY(U,$J,358.3,14852,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14852,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Unspec Breast
 ;;^UTILITY(U,$J,358.3,14852,1,4,0)
 ;;=4^D05.10
 ;;^UTILITY(U,$J,358.3,14852,2)
 ;;=^5001929
 ;;^UTILITY(U,$J,358.3,14853,0)
 ;;=D50.0^^62^698^97
 ;;^UTILITY(U,$J,358.3,14853,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14853,1,3,0)
 ;;=3^Iron Deficiency Anemia Secondary to Blood Loss
 ;;^UTILITY(U,$J,358.3,14853,1,4,0)
 ;;=4^D50.0
 ;;^UTILITY(U,$J,358.3,14853,2)
 ;;=^267971
 ;;^UTILITY(U,$J,358.3,14854,0)
 ;;=D50.9^^62^698^98
 ;;^UTILITY(U,$J,358.3,14854,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14854,1,3,0)
 ;;=3^Iron Deficiency Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,14854,1,4,0)
 ;;=4^D50.9
 ;;^UTILITY(U,$J,358.3,14854,2)
 ;;=^5002283
 ;;^UTILITY(U,$J,358.3,14855,0)
 ;;=C46.9^^62^698^99
 ;;^UTILITY(U,$J,358.3,14855,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14855,1,3,0)
 ;;=3^Kaposi's Sarcoma,Unspec
 ;;^UTILITY(U,$J,358.3,14855,1,4,0)
 ;;=4^C46.9
 ;;^UTILITY(U,$J,358.3,14855,2)
 ;;=^5001108
 ;;^UTILITY(U,$J,358.3,14856,0)
 ;;=C22.0^^62^698^100
 ;;^UTILITY(U,$J,358.3,14856,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14856,1,3,0)
 ;;=3^Liver Cell Carcinoma
 ;;^UTILITY(U,$J,358.3,14856,1,4,0)
 ;;=4^C22.0
 ;;^UTILITY(U,$J,358.3,14856,2)
 ;;=^5000933
 ;;^UTILITY(U,$J,358.3,14857,0)
 ;;=D05.02^^62^698^101
 ;;^UTILITY(U,$J,358.3,14857,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14857,1,3,0)
 ;;=3^Lobular Carcinoma in Situ,Left Breast
 ;;^UTILITY(U,$J,358.3,14857,1,4,0)
 ;;=4^D05.02
 ;;^UTILITY(U,$J,358.3,14857,2)
 ;;=^5001928
 ;;^UTILITY(U,$J,358.3,14858,0)
 ;;=D05.01^^62^698^102
 ;;^UTILITY(U,$J,358.3,14858,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14858,1,3,0)
 ;;=3^Lobular Carcinoma in Situ,Right Breast
 ;;^UTILITY(U,$J,358.3,14858,1,4,0)
 ;;=4^D05.01
 ;;^UTILITY(U,$J,358.3,14858,2)
 ;;=^5001927
 ;;^UTILITY(U,$J,358.3,14859,0)
 ;;=D05.00^^62^698^103
 ;;^UTILITY(U,$J,358.3,14859,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14859,1,3,0)
 ;;=3^Lobular Carcinoma in Situ,Unspec Breast
 ;;^UTILITY(U,$J,358.3,14859,1,4,0)
 ;;=4^D05.00
 ;;^UTILITY(U,$J,358.3,14859,2)
 ;;=^5001926
 ;;^UTILITY(U,$J,358.3,14860,0)
 ;;=R59.0^^62^698^62
 ;;^UTILITY(U,$J,358.3,14860,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14860,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Localized
 ;;^UTILITY(U,$J,358.3,14860,1,4,0)
 ;;=4^R59.0
 ;;^UTILITY(U,$J,358.3,14860,2)
 ;;=^5019529
